The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The non-invasive prenatal testing (NIPT) market has experienced a remarkable surge in recent years, showcasing substantial growth in both historical and forecast periods. With the market size projected to reach $5.44 billion in 2024 and a forecasted increase to $9.43 billion by 2028 at a CAGR of 14.7%, several factors contribute to this upward trajectory.

Historical Growth Factors

• Improved Accuracy and Reduced Risk: Technological advancements have led to enhanced accuracy and reduced risks associated with NIPT.
• Increased Maternal Age: A significant factor contributing to growth is the rising trend of women opting for pregnancy at later stages in life.
• Growing Awareness and Clinical Guidelines: Greater awareness and adherence to clinical guidelines have propelled the adoption of NIPT.

Forecasted Growth Trends

• Expanding Test Offerings: The market is expected to witness growth due to an increase in the types of tests offered.
• Wider Accessibility: Improved accessibility of NIPT services will contribute to market expansion.
• Telemedicine and Digital Health: The integration of telemedicine and digital health technologies will play a pivotal role in the growth of NIPT.

The Role of Increasing Maternal Age in Driving NIPT Market Growth
Increasing maternal age emerges as a key factor influencing the growth of the NIPT market. Factors such as pursuing education, career, delayed marriage, and improved contraception contribute to delayed childbirth. The subsequent higher risk of chromosomal abnormalities prompts expectant mothers to opt for NIPT. The statistics support this trend:

• In 2022, provisional birth rates for women aged 35-39 and 40-44 increased by 2% and 4%, respectively.
• Birth rates for women aged 45-49 surged by 12%, marking the first change in this rate since 2015.

As maternal age continues to rise, NIPT remains a crucial tool for assessing pregnancy health.

Advancements In Next-Generation Sequencing: Transforming NIPT Research
Next-generation sequencing (NGS) has revolutionized NIPT research by increasing throughput, scalability, and speed. Major companies like Illumina, Eurofins, Natera, Roche, and Annoroad leverage NGS to optimize DNA testing processes. Notable developments include:

• CFDA approval for NGS instrument NextSeq 550AR by Annoroad.
• The transformative impact of NGS on reducing time and cost, while enhancing genomic and DNA testing outcomes.

Industry Collaborations: Echelon’s Acquisition of Cradle Genomics
In May 2021, Echelon Diagnostics collaborated with Cradle Genomics, marking a significant move in the NIPT landscape. Echelon’s expertise in genomic healthcare AI imaging analysis synergizes with Cradle Genomics, a specialist in non-invasive prenatal testing services. This collaboration aims to accelerate the development of Cradle’s cellular-based NIPT products, showcasing the industry’s commitment to innovation.

View More On The Non-invasive Prenatal Testing Market Report 2024 – https://www.thebusinessresearchcompany.com/report/non-invasive-prenatal-testing-global-market-report

Market Segmentation and Regional Dominance
The non-invasive prenatal testing market is segmented based on type, application, and end-user:

1. Type: Consumables and Instruments
2. Application: Trisomy, Microdeletion, Genetics, Rh factor
3. End User: Hospital and Diagnostic Labs

Regional Dominance: North America Leads
In 2023, North America emerged as the largest region in the NIPT market. The region’s robust healthcare infrastructure, coupled with increasing awareness and adoption of advanced technologies, contributed to its dominance. The trend is expected to persist with the region playing a pivotal role in shaping the future of the NIPT market.

Key Players Shaping the NIPT Landscape
Major companies operating in the NIPT market include:

• F. Hoffmann-La Roche AG
• Illumina Inc.
• Laboratory Corporation of America Holdings
• Natera Inc.
• BGI Diagnosis Co Ltd.
• Berry Genomics Co
• LifeCodexx AG
• Myriad Genetics Inc.
• NIPD Genetics Co Ltd.
• Sequenom Inc.
• Annoroad Gene Technology Co Ltd.
• Centogene AG
• Counsyl Inc.
• EUROFINS Genoma Group
• Eurofins Scientific SE
• QIAGEN NV
• MedGenome Labs Ltd.
• Progenity Inc.

Request A Sample Of The Global Non-invasive Prenatal Testing Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=2492&type=smp